Sources

What MatchMedi cites, embeds, and links.

Source use is part of the safety model. Some sources can be embedded with attribution. Others are link-only until reuse terms are cleared.

Source coverage by condition

Which sources power each condition page.

This table shows the source backbone behind each condition page. No page is a treatment recommender.

Condition	Coverage	Registered sources	Next review need
Melanoma	In-depth guide	Melanoma Treatment (PDQ) - Patient Version Melanoma Treatment (PDQ) - Health Professional Version	Keep extending melanoma's stage and mutation pages; every other condition already has a sourced options-by-country map.
Lung cancer	Options mapped	Non-Small Cell Lung Cancer Treatment (PDQ) - Patient Version	Extend subtype and biomarker detail as new sources pass verification.
Breast cancer	Options mapped	Breast Cancer Treatment (PDQ) - Patient Version	Extend subtype detail as receptor-status sources pass verification.
Colorectal cancer	Options mapped	Colon Cancer Treatment (PDQ) - Patient Version	Split colon and rectal tracks further as source-backed biomarker records expand.
Leukemia	Options mapped	Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version Adult Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version Chronic Lymphocytic Leukemia Treatment (PDQ) - Patient Version Chronic Myeloid Leukemia Treatment (PDQ) - Patient Version	Extend subtype-specific AML, ALL, CLL, and CML detail as research records pass verification.
Leukemia / lymphoma	Options mapped	Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version Adult Non-Hodgkin Lymphoma Treatment (PDQ) - Patient Version	Use /cancers/leukemia for leukemia; lymphoma detail continues to expand.
Pediatric solid tumors	Options mapped	NCI Childhood Cancers	Extend the pediatric source map and reviewer pipeline as new options pass verification.
Adrenocortical carcinoma	Options mapped		Extend coverage for this condition as new sources pass verification.
Amyotrophic lateral sclerosis (ALS)	Options mapped		Extend coverage for this condition as new sources pass verification.
Anal cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Appendiceal cancer / pseudomyxoma peritonei	Options mapped		Extend coverage for this condition as new sources pass verification.
Atypical hemolytic uremic syndrome (aHUS)	Options mapped		Extend coverage for this condition as new sources pass verification.
Beta-thalassemia	Options mapped		Extend coverage for this condition as new sources pass verification.
Biliary tract cancer / cholangiocarcinoma	Options mapped		Extend coverage for this condition as new sources pass verification.
CNS glioma (brain tumor)	Options mapped		Extend coverage for this condition as new sources pass verification.
Cancer of unknown primary (CUP)	Options mapped		Extend coverage for this condition as new sources pass verification.
Cervical cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Cystic fibrosis	Options mapped		Extend coverage for this condition as new sources pass verification.
Duchenne muscular dystrophy (DMD)	Options mapped		Extend coverage for this condition as new sources pass verification.
Endometrial cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Esophageal cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Fabry disease	Options mapped		Extend coverage for this condition as new sources pass verification.
Gastric / gastro-oesophageal junction cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Gaucher disease	Options mapped		Extend coverage for this condition as new sources pass verification.
Generalized myasthenia gravis (gMG)	Options mapped		Extend coverage for this condition as new sources pass verification.
Gestational trophoblastic disease / neoplasia	Options mapped		Extend coverage for this condition as new sources pass verification.
Head and neck cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Hemophilia A / B	Options mapped		Extend coverage for this condition as new sources pass verification.
Hepatocellular carcinoma (liver cancer)	Options mapped		Extend coverage for this condition as new sources pass verification.
Hereditary angioedema (HAE)	Options mapped		Extend coverage for this condition as new sources pass verification.
Huntington's disease	Options mapped		Extend coverage for this condition as new sources pass verification.
Idiopathic pulmonary fibrosis (IPF)	Options mapped		Extend coverage for this condition as new sources pass verification.
Inherited retinal dystrophy (RPE65)	Options mapped		Extend coverage for this condition as new sources pass verification.
Langerhans cell histiocytosis	Options mapped		Extend coverage for this condition as new sources pass verification.
Merkel cell carcinoma	Options mapped		Extend coverage for this condition as new sources pass verification.
Mesothelioma	Options mapped		Extend coverage for this condition as new sources pass verification.
Mucopolysaccharidosis (MPS)	Options mapped		Extend coverage for this condition as new sources pass verification.
NUT carcinoma	Options mapped		Extend coverage for this condition as new sources pass verification.
Neuroendocrine tumor (NET)	Options mapped		Extend coverage for this condition as new sources pass verification.
Neurofibromatosis (NF1 / NF2)	Options mapped		Extend coverage for this condition as new sources pass verification.
Neuromyelitis optica spectrum disorder (NMOSD)	Options mapped		Extend coverage for this condition as new sources pass verification.
Non-melanoma skin cancer (BCC / cSCC)	Options mapped		Extend coverage for this condition as new sources pass verification.
Ovarian cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Pancreatic cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Paroxysmal nocturnal hemoglobinuria (PNH)	Options mapped		Extend coverage for this condition as new sources pass verification.
Penile cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Phenylketonuria (PKU)	Options mapped		Extend coverage for this condition as new sources pass verification.
Pompe disease	Options mapped		Extend coverage for this condition as new sources pass verification.
Prostate cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Pulmonary arterial hypertension (PAH)	Options mapped		Extend coverage for this condition as new sources pass verification.
Renal cell carcinoma (kidney cancer)	Options mapped		Extend coverage for this condition as new sources pass verification.
Sarcoma (incl. GIST)	Options mapped		Extend coverage for this condition as new sources pass verification.
Sickle cell disease	Options mapped		Extend coverage for this condition as new sources pass verification.
Spinal muscular atrophy (SMA)	Options mapped		Extend coverage for this condition as new sources pass verification.
Testicular germ cell cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Thymic carcinoma / thymoma	Options mapped		Extend coverage for this condition as new sources pass verification.
Thyroid cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Transthyretin (ATTR) amyloidosis	Options mapped		Extend coverage for this condition as new sources pass verification.
Tuberous sclerosis complex (TSC)	Options mapped		Extend coverage for this condition as new sources pass verification.
Tumor-agnostic / NTRK fusion-positive solid tumors	Options mapped		Extend coverage for this condition as new sources pass verification.
Urothelial / bladder cancer	Options mapped		Extend coverage for this condition as new sources pass verification.
Uveal melanoma	Options mapped		Extend coverage for this condition as new sources pass verification.
Vulvar / vaginal cancer	Options mapped		Extend coverage for this condition as new sources pass verification.

open-embed

Melanoma Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary patient-facing source for melanoma overview and treatment categories.

Registered citations: 7

Open source

open-embed

Melanoma Treatment (PDQ) - Health Professional Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Professional detail source for mutation and treatment-option derivation.

Registered citations: 1

Open source

open-embed

Non-Small Cell Lung Cancer Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for the lung-cancer overview entry point.

Registered citations: 1

Open source

open-embed

Breast Cancer Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for the breast-cancer overview entry point.

Registered citations: 1

Open source

open-embed

Colon Cancer Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for the colorectal-cancer overview entry point.

Registered citations: 1

Open source

open-embed

Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Source for initial leukemia entry point; not a complete leukemia module.

Registered citations: 3

Open source

open-embed

Adult Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary patient-facing source for adult ALL overview and source mapping.

Registered citations: 1

Open source

open-embed

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary patient-facing source for childhood ALL; pediatric leukemia needs separate handling.

Registered citations: 2

Open source

open-embed

Chronic Lymphocytic Leukemia Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary patient-facing source for CLL overview and source mapping.

Registered citations: 1

Open source

open-embed

Chronic Myeloid Leukemia Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary patient-facing source for CML overview and BCR-ABL/phase source mapping.

Registered citations: 1

Open source

open-embed

Chronic Myeloid Leukemia Treatment (PDQ) - Health Professional Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Professional source for CML treatment-context mapping, including TKI and transplant language.

Registered citations: 1

Open source

open-embed

Stem Cell and Bone Marrow Transplants for Cancer

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Patient-facing transplant source. Use for transplant process and risks, not to decide transplant fit.

Registered citations: 1

Open source

open-embed

Discontinuing Nilotinib in Patients with CML

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: context-only

Can support patient-facing summaries when attribution and context are shown.

Context source for treatment-free remission and careful monitoring after TKI discontinuation in selected CML patients.

Registered citations: 1

Open source

open-embed

Adult Non-Hodgkin Lymphoma Treatment (PDQ) - Patient Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Source for initial lymphoma entry point; not a complete lymphoma module.

Registered citations: 1

Open source

open-embed

Childhood Cancers

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Pediatric cancer entry source; deep pediatric pages require additional source mapping.

Registered citations: 1

Open source

open-embed

NCI Dictionary of Cancer Terms

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary glossary source.

Registered citations: 0

Open source

open-embed

Photodynamic Therapy to Treat Cancer

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for PDT as local light-activated treatment; does not make PDT a melanoma systemic-treatment claim.

Registered citations: 1

Open source

open-embed

Lasers to Treat Cancer

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for laser therapy as a local treatment and procedural tool; use carefully for melanoma only as local-modality context.

Registered citations: 1

Open source

open-embed

Hyperthermia to Treat Cancer

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Primary source for heat-based cancer treatment categories; emphasizes limited availability and use with other treatments.

Registered citations: 1

Open source

open-embed

NCI Drug Dictionary: Hyperbaric Oxygen

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: context-only

Can support patient-facing summaries when attribution and context are shown.

Context source for hyperbaric oxygen; patient pages must not present HBOT as proven melanoma treatment.

Registered citations: 1

Open source

open-embed

Cardiopulmonary Syndromes (PDQ) - Health Professional Version

National Cancer Institute

government-cancer-informationconfidence: highpatient claim: context-only

Can support patient-facing summaries when attribution and context are shown.

Supportive-care context for oxygen use in cancer-related dyspnea and hypoxemia; not a melanoma anti-cancer treatment source.

Registered citations: 1

Open source

open-embed

ClinicalTrials.gov API

National Library of Medicine

trial-registryconfidence: highpatient claim: context-only

Can support patient-facing summaries when attribution and context are shown.

Trial registry API used as secondary/fallback trial source.

Registered citations: 6

Open source

open-embed

PubMed

National Library of Medicine

peer-reviewed-paperconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Bibliographic source for peer-reviewed biomedical literature.

Registered citations: 1

Open source

link-only

KeChow Pharma

Shanghai KeChow Pharma

companyconfidence: mediumpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Company source; use only for approval/availability context and verify against regulator/trial sources.

Registered citations: 1

Open source

open-embed

NCI Clinical Trials Search API

National Cancer Institute

trial-registryconfidence: highpatient claim: context-only

Can support patient-facing summaries when attribution and context are shown.

Primary cancer trial search source.

Registered citations: 4

Open source

terms-review

CIViC: Clinical Interpretation of Variants in Cancer

CIViC

peer-reviewed-paperconfidence: mediumpatient claim: context-only

Useful candidate source, but terms need review before embedding clinical text.

Open cancer variant evidence candidate. Verify current license before embedded quotation.

Registered citations: 0

Open source

open-embed

FDA Oncology Center of Excellence

U.S. Food and Drug Administration

regulatorconfidence: highpatient claim: yes

Can support patient-facing summaries when attribution and context are shown.

Drug approvals and labeling references.

Registered citations: 6

Open source

link-only

NCCN Guidelines for Patients

National Comprehensive Cancer Network

professional-guidelineconfidence: highpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Link-only posture until reuse terms are cleared.

Registered citations: 0

Open source

terms-review

국가암정보센터

National Cancer Information Center Korea

government-cancer-informationconfidence: highpatient claim: yes

Useful candidate source, but terms need review before embedding clinical text.

Primary Korean source candidate. API reuse terms require review.

Registered citations: 3

Open source

link-only

China Center for Drug Evaluation

National Medical Products Administration

regulatorconfidence: highpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Chinese regulator/drug evaluation source. Use for approval research and link out.

Registered citations: 0

Open source

link-only

National Medical Products Administration

China National Medical Products Administration

regulatorconfidence: highpatient claim: yes

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Chinese regulator source for drug approval and conditional marketing status.

Registered citations: 1

Open source

link-only

Chinese Clinical Trial Registry

trial-registryconfidence: mediumpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

China trial registry source.

Registered citations: 0

Open source

link-only

がん情報サービス

National Cancer Center Japan

government-cancer-informationconfidence: highpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Japanese cancer information source; link primarily until reuse terms are reviewed.

Registered citations: 1

Open source

link-only

PMDA

Pharmaceuticals and Medical Devices Agency Japan

regulatorconfidence: highpatient claim: context-only

Link out and use carefully. Do not embed or quote heavily without clearer reuse rights.

Japan drug approval and safety information source.

Registered citations: 1

Open source

Source-use rules

Class	How we use it	Examples
open-embed	Use with attribution and last-checked dates in summaries.	NCI, FDA, ClinicalTrials.gov
link-only	Link out, but avoid embedding long or restricted content.	NCCN, PMDA, NMPA context
terms-review	Use sparingly until reuse terms are reviewed.	CIViC, KCIC API reuse

High confidence

Government, regulator, registry

Used for approval status, trial listings, and public cancer information.

Medium confidence

Context sources

Company pages or variant databases may provide leads, but need cross-checking.

Unresolved

Not for strong claims

If terms or exact records are unclear, they do not support strong treatment claims.